Jabil Bolsters Sustainable Packaging Capabilities with Acquisition of Ecologic Brands™
14.1.2021 16:45:00 EET | Business Wire | Press release
Jabil Inc. (NYSE: JBL) today announced the acquisition of Ecologic Brands, Inc., a leading provider of sustainable packaging specializing in paper bottle and paper-based packaging solutions. Ecologic’s Manteca, California-based operation will join the Jabil Packaging Solutions division, significantly enhancing Jabil’s sustainable packaging platform and offerings for consumer packaged goods (CPG) customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005367/en/
Jabil Inc. today announced the acquisition of Ecologic Brands, Inc., a leading provider of sustainable packaging specializing in paper bottle and paper-based packaging solutions. (Photo: Business Wire)
“By fueling Ecologic’s unique paper bottle technology with Jabil’s advanced manufacturing solutions and global scale, we aim to help all consumer brands dramatically reduce plastics in packaging worldwide,” said Jason Paladino, senior vice president of Jabil and CEO of Jabil Packaging Solutions. “We’re thrilled to be adding a talented team plus unique and innovative products that directly support our customer demands and Jabil’s enterprise sustainability goals.”
In Ecologic, Jabil Packaging Solutions gains a commercially mature paper bottle solution enabled by deep material expertise and innovative manufacturing processes. Major CPG brands including L’Oréal and Seventh Generation rely on Ecologic’s eco.bottle® to significantly reduce plastic packaging and advance their sustainability goals.
“Ecologic and L’Oreal broke new ground when we incubated the world’s first shower-safe paper bottle for the Seed Phytonutrients project. We’re taking things a step further by bringing this innovative packaging solution to our market-leading Matrix and Redken Brands,” said Shane Wolf, president worldwide, American Professional Brands, L’Oréal Professional Products Division. “Jabil is synonymous with innovation, engineering, automation and scale, so we can only imagine the solutions that will emerge through its union with Ecologic Brands. The possibilities and accessibility for sustainable packaging options are now limitless.”
“Ecologic has been a great partner over the past decade in helping us reimagine the laundry bottle and we’re thrilled to see the acquisition by Jabil,” said Joey Bergstein, CEO of Seventh Generation. “The world needs solutions at scale that reduce plastic waste and improve circularity. Jabil's global scale and deep engineering expertise will propel Ecologic's sustainable packaging solutions to a global footprint, in every category and format type. It’s truly a win for customers, the planet and the industry.”
“I am so proud that our paper bottle was the world’s first breakthrough technology that helps solve the growing environmental challenges caused by plastic,” said Julie Corbett, founder and CEO of Ecologic Brands. “Our pioneering efforts created and validated market opportunity, and now, Jabil provides the ideal mix of global footprint, manufacturing excellence and a customer-first culture to fully pursue our vision of leadership.”
While the team and operations will join Jabil, the company will continue to utilize the Ecologic name as its sustainable packaging product platform. For more information about Ecologic, visit ecologicbrands.com.
About Jabil:
Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005367/en/
Contact information
Media Contact
Erin Vadala
Warner Communications
+1 978-468-3076
erin@warnerpr.com
Europe Media Contact
Kirsten Oosterhof
Jabil
+44 (0)7342 073 248
kirsten_oosterhof@jabil.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom